Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study (Q47365819)

14 January 2018

title

Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study (English)

1 reference

14 January 2018

0 references

1 reference

4

1 reference

14 January 2018

Davood Khalili

object named as

Davood Khalili

1

0 references

Fereidoun Azizi

6

object named as

Fereidoun Azizi

1 reference

14 January 2018

Farzad Hadaegh

2

1 reference

14 January 2018

Hamid Soori

3

1 reference

14 January 2018

Mohammadreza Bozorgmanesh

5

1 reference

14 January 2018

language of work or name

English

0 references

publication date

19 July 2012

1 reference

14 January 2018

American Journal of Epidemiology

published in

1 reference

14 January 2018

volume

176

1 reference

14 January 2018

issue

3

1 reference

14 January 2018

page(s)

177-186

1 reference

14 January 2018

Definition of high risk individuals to optimise strategies for primary prevention of cardiovascular diseases

cites work

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Risk scores for prediction of coronary heart disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

An updated coronary risk profile. A statement for health professionals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Prediction of first coronary events with the Framingham score: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Decision curve analysis: a novel method for evaluating prediction models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Assessing the performance of prediction models: a framework for traditional and novel measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Systematic Examination of the Updated Framingham Heart Study General Cardiovascular Risk Profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Using relative utility curves to evaluate risk prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Recalibration of a Framingham risk equation for a rural population in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Cardiovascular risk prediction tools for populations in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

21 January 2018

Life course epidemiology

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Validity of the Framingham point scores in the elderly: Results from the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Glucose intolerance and risk of cardiovascular disease in Iranian men and women: results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

New and known type 2 diabetes as coronary heart disease equivalent: results from 7.6 year follow up in a Middle East population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Aspirin chemoprevention: one size does not fit all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

Intermittent claudication. Incidence in the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS204

21 January 2018

Identifiers

DOI

10.1093/AJE/KWS204

1 reference

14 January 2018

PubMed ID

22814370

1 reference

14 January 2018